Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 238 of the 238 references it cites were found in a registry or an index.

Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease

Open access
Puengel, Tobias, Liu, Hanyang, Guillot, Adrien, Heymann, Felix, Tacke, Frank, Peiseler, Moritz · 2022 · International Journal of Molecular Sciences

Abstract

Nonalcoholic fatty liver disease (NAFLD) and its progressive form nonalcoholic steatohepatitis (NASH) comprise a spectrum of chronic liver diseases in the global population that can lead to end-stage liver disease and hepatocellular carcinoma (HCC). NAFLD is closely linked to the metabolic syndrome, and comorbidities such as type 2 diabetes, obesity and insulin resistance aggravate liver disease, while NAFLD promotes cardiovascular risk in affected patients. The pathomechanisms of NAFLD are multifaceted, combining hepatic factors including lipotoxicity, mechanisms of cell death and liver inflammation with extrahepatic factors including metabolic disturbance and dysbiosis. Nuclear receptors (NRs) are a family of ligand-controlled transcription factors that regulate glucose, fat and cholesterol homeostasis and modulate innate immune cell functions, including liver macrophages. In parallel with metabolic derangement in NAFLD, altered NR signaling is frequently observed and might be involved in the pathogenesis. Therapeutically, clinical data indicate that single drug targets thus far have been insufficient for reaching patient-relevant endpoints. Therefore, combinatorial treatment strategies with multiple drug targets or drugs with multiple mechanisms of actions could possibly bring advantages, by providing a more holistic therapeutic approach. In this context, peroxisome proliferator-activated receptors (PPARs) and other NRs are of great interest as they are involved in wide-ranging and multi-organ activities associated with NASH progression or regression. In this review, we summarize recent advances in understanding the pathogenesis of NAFLD, focusing on mechanisms of cell death, immunometabolism and the role of NRs. We outline novel therapeutic strategies and discuss remaining challenges.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3390/ijms23052668

Cites

238 of 238 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 The spectrum of nonalcoholic fatty liver disease (NAFLD). NAFLD is a chronic liver disease that comprises a spectrum of metabolic liver diseases ranging from steatosis to nonalcoholic steatohepatitis (NASH) to end-stage liver disease including cirrhosis and hepatocellular carcinoma. Unique about the pathogenesis of NAFLD is the connected nature of the disease promoting events. Overnutrition leads to metabolic dysregulation resulting in cell stress and lipotoxicity. This triggers inflammation and recruitment of immune cells to the liver. Cell stress and inflammatory stress lead to hepatocyte death, which in NAFLD can be in different forms of cell death. (Created with Biorender.com, accessed on 23 February 2022).
Figure 1 The spectrum of nonalcoholic fatty liver disease (NAFLD). NAFLD is a chronic liver disease that comprises a spectrum of metabolic liver diseases ranging from steatosis to nonalcoholic steatohepatitis (NASH) to end-stage liver disease including cirrhosis and hepatocellular carcinoma. Unique about the pathogenesis of NAFLD is the connected nature of the disease promoting events. Overnutrition leads to metabolic dysregulation resulting in cell stress and lipotoxicity. This triggers inflammation and recruitment of immune cells to the liver. Cell stress and inflammatory stress lead to hepatocyte death, which in NAFLD can be in different forms of cell death. (Created with Biorender.com, accessed on 23 February 2022).CC BY · PubMed Central
Figure 2 Nuclear receptors (NRs) modulate metabolism, inflammation, and fibrosis in NAFLD. Multiple NRs (e.g., PPAR α, PPAR β/δ, PPAR γ, FXR, LXR and LRH1) expressed by immune and liver parenchymal cells (hepatocytes, HSCs, macrophages, DCs and T cells) are activated by lipid deposition and bile acids. Binding RXR, NRs modulate lipid metabolism through downstream mediators (such as SREBP1c). In NAFLD, lipid-vesicle loaded hepatocytes secrete cytokines (such as TGFβ) and ROS to modulate the immune response. Hepatocyte-derived cytokines, FAs and Bas further shape the immune response and KC polarization. Coordinating with hepatocytes, activated KCs induce the activation of HSCs to myofibroblasts, which eventually promote fibrogenesis. In addition, activated DCs orchestrate the T cell immune response. NAFLD: non-alcoholic fatty liver disease; PPAR: peroxisome proliferator-activated receptor; FXR: farnesoid X receptor; LXR: liver X receptor; LRH1: liver receptor homolog 1; RXR: retinoid X receptor; SREBP1c: sterol regulatory element binding protein 1c; FAs: fatty acids; BAs: bile acids; HSC: hepatic stellate cell; KC: Kupffer cell; DC: dendritic cell; ROS: reactive oxygen species; TNF: tumor necrosis factor; TGF: transforming growth factor. (Created with Biorender.com, accessed on 23 February 2020).
Figure 2 Nuclear receptors (NRs) modulate metabolism, inflammation, and fibrosis in NAFLD. Multiple NRs (e.g., PPAR α, PPAR β/δ, PPAR γ, FXR, LXR and LRH1) expressed by immune and liver parenchymal cells (hepatocytes, HSCs, macrophages, DCs and T cells) are activated by lipid deposition and bile acids. Binding RXR, NRs modulate lipid metabolism through downstream mediators (such as SREBP1c). In NAFLD, lipid-vesicle loaded hepatocytes secrete cytokines (such as TGFβ) and ROS to modulate the immune response. Hepatocyte-derived cytokines, FAs and Bas further shape the immune response and KC polarization. Coordinating with hepatocytes, activated KCs induce the activation of HSCs to myofibroblasts, which eventually promote fibrogenesis. In addition, activated DCs orchestrate the T cell immune response. NAFLD: non-alcoholic fatty liver disease; PPAR: peroxisome proliferator-activated receptor; FXR: farnesoid X receptor; LXR: liver X receptor; LRH1: liver receptor homolog 1; RXR: retinoid X receptor; SREBP1c: sterol regulatory element binding protein 1c; FAs: fatty acids; BAs: bile acids; HSC: hepatic stellate cell; KC: Kupffer cell; DC: dendritic cell; ROS: reactive oxygen species; TNF: tumor necrosis factor; TGF: transforming growth factor. (Created with Biorender.com, accessed on 23 February 2020).CC BY · PubMed Central
Figure 3 Novel pharmacologic compounds targeting metabolic and inflammatory pathways in NAFLD. During development and progression of NAFLD, multiple signalling pathways are dysregulated. Preclinical and clinical studies identified many potential drug targets for the treatment of nonalcoholic steatohepatitis and fibrosis. Targeting metabolic and inflammatory mechanisms of action (blue) represent promising strategies, which led to the development of various therapeutic compounds (orange), which are currently under clinical investigation. SCD1, stearoyl-CoA desaturase 1; PPAR, peroxisome proliferator-activated receptor; FGF, fibroblast growth factor; FXR, Farnesoid X receptor; FFA, free fatty acids.
Figure 3 Novel pharmacologic compounds targeting metabolic and inflammatory pathways in NAFLD. During development and progression of NAFLD, multiple signalling pathways are dysregulated. Preclinical and clinical studies identified many potential drug targets for the treatment of nonalcoholic steatohepatitis and fibrosis. Targeting metabolic and inflammatory mechanisms of action (blue) represent promising strategies, which led to the development of various therapeutic compounds (orange), which are currently under clinical investigation. SCD1, stearoyl-CoA desaturase 1; PPAR, peroxisome proliferator-activated receptor; FGF, fibroblast growth factor; FXR, Farnesoid X receptor; FFA, free fatty acids.CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 238 references

Cited by

See all 100

Metadata

Authors
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M.
Affiliations
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin (DE)
  • Charité – Universitätsmedizin Berlin (DE)
Corresponding author
  • Tacke, Frank
  • Peiseler, Moritz
Venue
International Journal of Molecular Sciences
Publisher
MDPI AG
Published
2022-02-28
Volume
23
Issue
5
Pages
2668
ISSN
1422-0067 (ISSN-L)
OpenAlex
W4214523533
Cited by
95
References
238
Citations by year
2026: 10 · 2025: 15 · 2024: 30 · 2023: 22 · 2022: 18
FWCI
3.37
Type
journal article
Language
en
Open access
Locations
  • International Journal of Molecular Sciences (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
  • Deutsche Forschungsgemeinschaft (SFB/TRR296, CRC1382)
  • Berlin Institute of Health at Charité - Universitätsmedizin Berlin (CSP 21-1)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease Diagnosis and Treatment
  • Health Sciences › Medicine › Hepatology › Liver physiology and pathology
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
Keywords
non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, nuclear receptors, peroxisome proliferator-activated receptors, liver inflammation, liver fibrosis, metabolic syndrome, insulin resistance, immunometabolism, hepatocyte death, lipotoxicity, gut dysbiosis, hepatic macrophages, hepatocellular carcinoma, combination therapy
MeSH terms
Diabetes Mellitus, Type 2, Fibrosis, Carcinoma, Hepatocellular, Humans, Inflammation, Liver, Liver Neoplasms, Receptors, Cytoplasmic and Nuclear, Non-alcoholic Fatty Liver Disease

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. https://app.cochat.ai/papers/10.3390/ijms23052668
The paper
Puengel, T., Liu, H., Guillot, A., Heymann, F., Tacke, F., & Peiseler, M. (2022). Nuclear Receptors Linking Metabolism, Inflammation, and Fibrosis in Nonalcoholic Fatty Liver Disease. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms23052668

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.